StreetInsider.com News Articles

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 03 Jun 2026 07:01:00 -0400

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.22, representing the closing price of Invivyd’s common stock on the grant date. Each option vests

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 03 Jun 2026 07:01:00 -0400

The options have a per share exercise price of $1.22, representing the closing price of Invivyd’s common stock on the grant date. Each option vests

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 03 Jun 2026 07:01:00 -0400

The options have a per share exercise price of $1.22, representing the closing price of Invivyd’s common stock on the grant date. Each option vests

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 03 Jun 2026 07:01:00 -0400

The options have a per share exercise price of $1.22, representing the closing price of Invivyd’s common stock on the grant date. Each option vests

Invivyd completes enrollment in phase 3 COVID antibody trial

Mon, 01 Jun 2026 07:02:13 -0400

Invivyd Inc. (NASDAQ: IVVD) announced completion of enrollment in its DECLARATION clinical trial, a phase 3 study evaluating VYD2311, an investigational monoclonal antibody for COVID-19 prevention.

The randomized, placebo-controlled trial enrolled approximately 2,400 participants, including about 500 additional subjects following a pre-specified sample size re-estimation analysis. The study evaluates two dosing regimens of VYD2311 administered via intramuscular injection: a single dose and monthly doses, both compared to placebo.

The trial aims to assess the safety and efficacy of VYD2311 in preventing symptomatic COVID-19 at three months in a broad population including adults and adolescents. Top-line results are expected in late third quarter

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Mon, 01 Jun 2026 07:01:00 -0400

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated
A second arm is evaluating monthly IM doses of VYD2311 versus placebo to demonstrate the safety and efficacy of more frequent dosing to support individual choice should at-risk people seek periodic extra protection from COVID
Invivyd previously conducted a pre-specified sample size re-estimation analysis designed to add statistical power robustness given future COVID event rate

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Mon, 01 Jun 2026 07:01:00 -0400

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated
A second arm is evaluating monthly IM doses of VYD2311 versus placebo to demonstrate the safety and efficacy of more frequent dosing to support individual choice should at-risk people seek periodic extra protection from COVID
Invivyd previously conducted a pre-specified sample size re-estimation analysis designed to add statistical power robustness given future COVID event rate

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Mon, 01 Jun 2026 07:01:00 -0400

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated
A second arm is evaluating monthly IM doses of VYD2311 versus placebo to demonstrate the safety and efficacy of more frequent dosing to support individual choice should at-risk people seek periodic extra protection from COVID
Invivyd previously conducted a pre-specified sample size re-estimation analysis designed to add statistical power robustness given future COVID event rate

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Mon, 01 Jun 2026 07:01:00 -0400

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated
A second arm is evaluating monthly IM doses of VYD2311 versus placebo to demonstrate the safety and efficacy of more frequent dosing to support individual choice should at-risk people seek periodic extra protection from COVID
Invivyd previously conducted a pre-specified sample size re-estimation analysis designed to add statistical power robustness given future COVID event rate

Invivyd to Participate in Upcoming Investor Events

Wed, 27 May 2026 07:01:00 -0400

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:

2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link

H.C. Wainwright “HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link

BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual

Live webcasts of the fireside chats will

Invivyd to Participate in Upcoming Investor Events

Wed, 27 May 2026 07:01:00 -0400

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:

2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link

H.C. Wainwright “HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link

BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual

Live webcasts of the fireside chats will

Invivyd to Participate in Upcoming Investor Events

Wed, 27 May 2026 07:01:00 -0400

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:

2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link

H.C. Wainwright “HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link

BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual

Live webcasts of the fireside chats will

Invivyd to Participate in Upcoming Investor Events

Wed, 27 May 2026 07:01:00 -0400

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:

2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link

H.C. Wainwright “HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link

BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual

Live webcasts of the fireside chats will

Form 4 Invivyd, Inc. For: May 19 Filed by: Royan Ajay

Thu, 21 May 2026 16:50:00 -0400
si-local-file:///var/storage/secattach/20260521/26536325.html

Form 4 Invivyd, Inc. For: May 19 Filed by: Royan Ajay

Thu, 21 May 2026 16:50:00 -0400
si-local-file:///var/storage/secattach/20260521/26536325.html

Form 4 Invivyd, Inc. For: May 19 Filed by: MCGUIRE TERRANCE

Thu, 21 May 2026 16:49:00 -0400
si-local-file:///var/storage/secattach/20260521/26536315.html

Form 4 Invivyd, Inc. For: May 19 Filed by: MCGUIRE TERRANCE

Thu, 21 May 2026 16:49:00 -0400
si-local-file:///var/storage/secattach/20260521/26536315.html

Form 4 Invivyd, Inc. For: May 19 Filed by: MCLAUGHLIN KEVIN F

Thu, 21 May 2026 16:49:00 -0400
si-local-file:///var/storage/secattach/20260521/26536318.html

Form 4 Invivyd, Inc. For: May 19 Filed by: MCLAUGHLIN KEVIN F

Thu, 21 May 2026 16:49:00 -0400
si-local-file:///var/storage/secattach/20260521/26536318.html

Form 4 Invivyd, Inc. For: May 19 Filed by: Berry Tamsin

Thu, 21 May 2026 16:48:00 -0400
si-local-file:///var/storage/secattach/20260521/26536298.html

Form 4 Invivyd, Inc. For: May 19 Filed by: Berry Tamsin

Thu, 21 May 2026 16:48:00 -0400
si-local-file:///var/storage/secattach/20260521/26536298.html

Form 4 Invivyd, Inc. For: May 19 Filed by: BOLNO PAUL

Thu, 21 May 2026 16:48:00 -0400
si-local-file:///var/storage/secattach/20260521/26536305.html

Form 4 Invivyd, Inc. For: May 19 Filed by: BOLNO PAUL

Thu, 21 May 2026 16:48:00 -0400
si-local-file:///var/storage/secattach/20260521/26536305.html

Form 4 Invivyd, Inc. For: May 19 Filed by: M28 Capital Management LP

Thu, 21 May 2026 16:48:00 -0400
si-local-file:///var/storage/secattach/20260521/26536308.html

Form 4 Invivyd, Inc. For: May 19 Filed by: M28 Capital Management LP

Thu, 21 May 2026 16:48:00 -0400
si-local-file:///var/storage/secattach/20260521/26536308.html